F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Very-Low-Density Lipoprotein (VLDL)-Producing and Hepatitis C Virus-Replicating HepG2 Cells Secrete No More Lipoviroparticles than VLDL-Deficient Huh7.5 Cells
Baptiste Jammart,Maud Michelet,Eve-Isabelle Pécheur,Romain Parent,Birke Bartosch,Fabien Zoulim,David Durantel +6 more
TL;DR: A new HCV cell culture model is developed based on engineered HepG2 cells stably replicating a blasticidin-tagged HCV JFH1 strain to study the interaction between HCV and lipoproteins, which suggests that there is no correlation between the ability of cells to simultaneously replicate HCV as well as secrete VLDL and their capacity to produce LVPs.
Journal ArticleDOI
Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies.
Fabien Zoulim,Fabien Zoulim +1 more
TL;DR: The search for new viral targets is mandatory to design combination strategies to prevent the emergence of resistant mutants and eventually clear viral infection.
Journal ArticleDOI
A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)
Christophe Corpechot,Olivier Chazouillères,Alexandra Rousseau,Dominique Guyader,François Habersetzer,P. Mathurin,Odile Goria,Patrick Potier,Anne Minello,C. Silvain,Armando Abergel,Maryline Debette-Gratien,Dominique Larrey,Olivier Roux,Jean-Pierre Bronowicki,Jérôme Boursier,V. de Ledhingen,Alexandra Heurgué-Berlot,Eric Nguyen-Khac,Fabien Zoulim,Isabelle Ollivier-Hourmand,Jean-Pierre Zarski,Gisèle N'Kontchou,Farid Gaouar,Tabassome Simon,R.E. Poupon +25 more
Journal ArticleDOI
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study
Victor de Ledinghen,Claire Laforest,Christophe Hézode,Stanislas Pol,Alain Renault,Laurent Alric,Dominique Larrey,Sophie Metivier,Albert Tran,Caroline Jezequel,Didier Samuel,Fabien Zoulim,Christelle Tual,Aurelie Pailhe,Severine Gibowski,Marc Bourlière,Eric Bellissant,Jean-Michel Pawlotsky +17 more
TL;DR: The findings support the concept of retreating with sofosbuvir + grazoprevir/elbasvir + ribavirin, for 16 weeks, genotype 1 or 4 DAA-experienced patients with proven NS5A or NS3 RASs.
Journal ArticleDOI
Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.
Franck Le Guerhier,Alexandre Thermet,Sylvianne Guerret,Michèle Chevallier,Catherine Jamard,Craig S. Gibbs,Christian Trepo,Lucyna Cova,Fabien Zoulim +8 more
TL;DR: The results suggest that combination of adefovir with DNA-vaccine may be able to induce a sustained antiviral effect in vivo.